Remove 2016 Remove Leads Remove Prescription
article thumbnail

The rise of prescription drug abuse and drug diversion

pharmaphorum

As prescription drug abuse has grown in the US and Europe, the diversion of such treatments from legitimate sources has also increased. Drug diversion is the channelling of prescription drugs from a medical source into the illegal market. The post The rise of prescription drug abuse and drug diversion appeared first on.

article thumbnail

Medicare savings won’t make a dent in healthcare costs

World of DTC Marketing

SUMMARY: Allowing Medicare to negotiate drug prices is popular with voters because the media has been focused on the high price of some drugs, but this measure won’t lead to lower healthcare costs. The drug industry is trying to convince voters that government negotiations with drug companies will lead to less innovation.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

GAO Report on DTC/Medicare spending flawed

World of DTC Marketing

This report is going to lead to more calls to limit DTC advertising. 1ne: Medicare Parts B and D and beneficiaries spent $560 billion on drugs from 2016 through 2018, $324 billion spent on advertised drugs. Do DTC ads lead to increased patient knowledge of chronic health issues? So let’s look at the contents.

article thumbnail

The current pharma business model is unsustainable

World of DTC Marketing

In pharma, growth depends on new products with hefty price tags when over 80% of voters want lower costs for their prescription drugs. According to JAMA , “in a cross-sectional study, between May 1, 2016, and May 31, 2021, there were 207 cancer drug approvals in oncology and malignant hematology. ” The U.S.

Pharma 210
article thumbnail

HeartBeam Announces Acquisition of LIVMOR Assets

Legacy MEDSearch

Founded in 2016, LIVMOR developed the Halo+ Atrial Fibrillation (AF) Detection System, the world’s first FDA-cleared prescription wearable for continuous cardiac rhythm monitoring. The acquisition extends HeartBeam’s reach in remote monitoring and detection with full ownership of an existing cutting-edge FDA-cleared product.

article thumbnail

Botanical drugs – what is the best way forward for regulatory and market approval?

European Pharmaceutical Review

1 For use as prescription drugs, a botanical product must be approved by the FDA: to date, only two have gained this approval. 2 It was first approved as Fulyzaq in December 2012 and in October 2016, Napo Pharmaceuticals launched the new brand, Mytesi. 3 Is two too few? 2012/1916).

Marketing 103
article thumbnail

Why we need to support healthcare’s vital acceleration

pharmaphorum

Secondly, pressure on healthcare spending is leading to greater consolidation. Mergers and acquisitions are contributing to consolidation, with about 2,600 healthcare deals globally in 2022, up from 1,500 in 2016. Moreover, new types of investors are emerging that have not traditionally invested in healthcare in the past.